UK markets closed

Biophytis SA (0D1W.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.9700+2.4330 (+453.07%)
At close: 4:45PM BST

Biophytis SA

Sorbonne University
BC 9, BAtiment A 4Eme Etage 4 place Jussieu Cedex 05
Paris 75005
33 1 44 27 23 00

Full-time employees25

Key executives

NameTitlePayExercisedYear born
Mr. Stanislas Veillet Ph.D.Chairman & CEO373.9kN/A1965
Ms. Evelyne NguyenChief Financial OfficerN/AN/A1962
Mr. Waly DiohChief Operating OfficerN/AN/A1969
Dr. Pierre J. DildaChief Scientific OfficerN/AN/A1970
Dr. Rene LafontScientific Advisor & Member of Scientific Advisory BoardN/AN/A1946
Mr. Benoit CanolleChief Bus. OfficerN/AN/AN/A
Mr. Rob van Maanen FFPM, M.B.A., M.D.Chief Medical OfficerN/AN/AN/A
Ms. _ TeylanFinancial ControllerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France.

Corporate governance

Biophytis SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.